Cargando…
Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays
BACKGROUND: Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ grafts. The 2 main kits to detect anti-HLA Ab in patient serum are commercialized by Immucor and One Lambda/ThermoFisher. We sought to compare the performance of both platforms. METHODS: Background-adjust...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682763/ https://www.ncbi.nlm.nih.gov/pubmed/29184907 http://dx.doi.org/10.1097/TXD.0000000000000734 |
_version_ | 1783278166003941376 |
---|---|
author | Clerkin, Kevin J. See, Sarah B. Farr, Maryjane A. Restaino, Susan W. Serban, Geo Latif, Farhana Li, Lingzhi Colombo, Paolo C. Vlad, George Ray, Bryan Vasilescu, Elena R. Zorn, Emmanuel |
author_facet | Clerkin, Kevin J. See, Sarah B. Farr, Maryjane A. Restaino, Susan W. Serban, Geo Latif, Farhana Li, Lingzhi Colombo, Paolo C. Vlad, George Ray, Bryan Vasilescu, Elena R. Zorn, Emmanuel |
author_sort | Clerkin, Kevin J. |
collection | PubMed |
description | BACKGROUND: Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ grafts. The 2 main kits to detect anti-HLA Ab in patient serum are commercialized by Immucor and One Lambda/ThermoFisher. We sought to compare the performance of both platforms. METHODS: Background-adjusted mean fluorescence intensity (MFI) values were used from both platforms to compare sera collected from 125 pretransplant and posttransplant heart and lung transplant recipients. RESULTS: Most HLA class I (94.5%) and HLA class II (89%) Abs with moderate to high MFI titer (≥4000) were detected by both assays. A modest correlation was observed between MFI values obtained from the 2 assays for both class I (r = 0.3, r(2) = 0.09, P < 0.0001) and class II Ab (r = 0.707, r(2) = 0.5, P < 0.0001). Both assays detected anti–class I and II Ab that the other did not; however, no specific HLA allele was detected preferentially by either of the 2 assays. For a limited number of discrepant sera, dilution resulted in comparable reactivity profiles between the 2 platforms. CONCLUSIONS: Immucor and One Lambda/ThermoFisher assays have a similar, albeit nonidentical, ability to detect anti-HLA Ab. Although the correlation between the assays was present, significant variances exist, some of which can be explained by a dilution-sensitive “prozone” effect. |
format | Online Article Text |
id | pubmed-5682763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-56827632017-11-28 Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays Clerkin, Kevin J. See, Sarah B. Farr, Maryjane A. Restaino, Susan W. Serban, Geo Latif, Farhana Li, Lingzhi Colombo, Paolo C. Vlad, George Ray, Bryan Vasilescu, Elena R. Zorn, Emmanuel Transplant Direct Clinical Method BACKGROUND: Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ grafts. The 2 main kits to detect anti-HLA Ab in patient serum are commercialized by Immucor and One Lambda/ThermoFisher. We sought to compare the performance of both platforms. METHODS: Background-adjusted mean fluorescence intensity (MFI) values were used from both platforms to compare sera collected from 125 pretransplant and posttransplant heart and lung transplant recipients. RESULTS: Most HLA class I (94.5%) and HLA class II (89%) Abs with moderate to high MFI titer (≥4000) were detected by both assays. A modest correlation was observed between MFI values obtained from the 2 assays for both class I (r = 0.3, r(2) = 0.09, P < 0.0001) and class II Ab (r = 0.707, r(2) = 0.5, P < 0.0001). Both assays detected anti–class I and II Ab that the other did not; however, no specific HLA allele was detected preferentially by either of the 2 assays. For a limited number of discrepant sera, dilution resulted in comparable reactivity profiles between the 2 platforms. CONCLUSIONS: Immucor and One Lambda/ThermoFisher assays have a similar, albeit nonidentical, ability to detect anti-HLA Ab. Although the correlation between the assays was present, significant variances exist, some of which can be explained by a dilution-sensitive “prozone” effect. Lippincott Williams & Wilkins 2017-10-02 /pmc/articles/PMC5682763/ /pubmed/29184907 http://dx.doi.org/10.1097/TXD.0000000000000734 Text en Copyright © 2017 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Clinical Method Clerkin, Kevin J. See, Sarah B. Farr, Maryjane A. Restaino, Susan W. Serban, Geo Latif, Farhana Li, Lingzhi Colombo, Paolo C. Vlad, George Ray, Bryan Vasilescu, Elena R. Zorn, Emmanuel Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title | Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title_full | Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title_fullStr | Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title_full_unstemmed | Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title_short | Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays |
title_sort | comparative assessment of anti-hla antibodies using two commercially available luminex-based assays |
topic | Clinical Method |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682763/ https://www.ncbi.nlm.nih.gov/pubmed/29184907 http://dx.doi.org/10.1097/TXD.0000000000000734 |
work_keys_str_mv | AT clerkinkevinj comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT seesarahb comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT farrmaryjanea comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT restainosusanw comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT serbangeo comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT latiffarhana comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT lilingzhi comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT colombopaoloc comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT vladgeorge comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT raybryan comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT vasilescuelenar comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays AT zornemmanuel comparativeassessmentofantihlaantibodiesusingtwocommerciallyavailableluminexbasedassays |